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Abstract
The implementation of pharmacogenomics (PGx) has come a long way since the dawn of utilizing pharmacogenomic data in
clinical patient care. However, the potential benefits of sharing PGx results have yet to be explored. In this paper, we explore
the willingness of patients to share PGx results, as well as the inclusion of family medication history in identifying potential
family members for pharmacogenomics cascade testing (PhaCT). The genetic similarities in families allow for identifying
potential gene variants prior to official preemptive testing. Once a candidate patient is determined, PhaCT can be initiated.
PhaCT recognizes that further cascade testing throughout a family can serve to improve precision medicine. In order to make
PhaCT feasible, we propose a novel shareable HIPAA-compliant informatics platform that will enable patients to manage
not only their own test results and medications but also those of their family members. The informatics platform will be an
external genomics system with capabilities to integrate with patients’ electronic health records. Patients will be given the
tools to provide information to and work with clinicians in identifying family members for PhaCT through this platform.
Offering patients the tools to share PGx results with their family members for preemptive testing could be the key to
empowering patients. Clinicians can utilize PhaCT to potentially improve medication adherence, which may consequently
help to distribute the burden of health management between patients, family members, providers, and payers.
Introduction
Over the last two decades, the incorporation of pharmaco-
genomics (PGx) into routine clinical practice has been
steadily increasing [1, 2]. Resources such as PharmGKB,
the Clinical Pharmacogenetics Implementation Consortium
(CPIC), and the Dutch Pharmacogenetics Working Group
(DPWG) have been advancing the translation of complex
PGx information into actionable phenotypes that are useful
for clinicians. More recently, the Electronic Medical
Records and Genomics (eMERGE) and the Implementing
Genomics in Practice (IGNITE) networks have focused on
embedding genomics data with electronic health records
(EHR) [3]. While programs such as eMERGE and IGNITE
have made strides in the use of PGx results in clinical
practice, there are still barriers to the widespread utilization
of PGx. For example, not many EHRs support discrete PGx
data that can be translated to Clinical Decision Support
(CDS), and many leading EHR vendors impose an extra fee
to support PGx modules. Moreover, reimbursement for PGx
testing is still done on a case-by-case basis by most insur-
ance companies. For example, Medicare will only pay for
CYP2D6 and CYP2C19 PGx testing for specific drugs or
disease conditions, while private health insurance payers
often vary in their willingness to pay for PGx testing.
Among other financial challenges, the additional costs
and inaccessibility of PGx data further demotivate health-
care systems and providers to implement PGx testing.
Fortunately, providers, payers, and patients understand the
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impact and importance of PGx [4]. For instance, the annual
burden of medication non-adherence is estimated to be $300
million [5]. In contrast, the validation of the effectiveness
of medications by PGx incentivizes patients towards
improved medication adherence [6]. From the perspective
of the payer, more health insurance companies are realizing
the financial benefits of PGx testing, which decreases
unnecessary utilization and costs, and are thus reimbursing
for PGx tests [7]. Furthermore, patients have a desire to
manage and share PGx results with family members. Unlike
tests such as bloodwork, which need to be repeated,
germline DNA does not change over the course of a per-
son’s life, and thus the long-term benefits of PGx results are
applicable over the lifetime of the patient. While research
has focused on EHR PGx integration within health systems,
little has been done to facilitate the sharing of PGx results
between family members and clinicians [8–10].
Current models for sharing PGx data
Direct-to-consumer (DTC) PGx tests often bypass the
review of a clinician and send results to patients directly,
and patients are in control of sharing their results with
clinicians. However, DTC PGx tests are marred by concerns
regarding test validity, quality, misinterpretation, and the
potential for inappropriate medical action. In contrast, the
analytical validity and accuracy of clinical PGx tests are
usually very robust (accuracy > 99%), and they are often
Clinical Laboratory Improvemennt Amendments (CLIA)-
certified or FDA-cleared. Figure 1 illustrates the workflow
of how patients typically receive clinical PGx test results at
present. First, the clinician assesses the patient’s need for a
PGx test and, if deemed necessary, orders the test. After the
laboratory receives the physician’s order, a test kit is sent to
the patient to collect the patient’s DNA sample. Currently,
most laboratories send PGx results as a plain text repre-
sentation of the interpretation report and transmit the results
to patients and providers using Health Level 7 (HL7)
v2 standard or a simple static pdf file [1]. Unfortunately,
static pdf files often become buried in emails or locked
inside EHRs and are thus not readily available to the patient.
Moreover, if a patient was tested for multiple pharmaco-
genes, the resulting multipage report is often too extensive
for the provider to interpret without CDS.
Preferences for sharing results
Although results may not be pertinent at the time of testing,
PGx tests have long-term implications. A recent study
involving 869 patients showed that 87% of patients
understood their PGx results and recognized the implica-
tions for the future usage of PGx [11]. Patients with a higher
level of understanding elected to share results with provi-
ders for the most optimum care in their health-decision
making [12–15]. After sharing results with providers, sev-
eral studies show that the majority of patients were satisfied
Fig. 1 Current typical
workflow of a clinical
pharmacogenomics (PGx) test
from ordering to reviewing.
First, a PGx test is ordered by
the clinician. Second, the
laboratory receives the
physician’s order and sends a
test kit to the patient to collect
the patient’s DNA sample. The
laboratory processes the
patient’s sample after collection,
and the raw genotyping data is
processed. Third, the raw
genotyping results are converted
into a human-readable format
and sent to the prescriber via
electronic health records (EHR),
email, or fax. Lastly, the results
are shared with the patient by the
physician.
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with the conversations they had with their health care pro-
viders (HCPs) and felt that the PGx results could be utilized
to improve their health [6, 16]. In addition, recent studies
have reported that most patients are willing to not only
share test results with providers but also with family
members (Table 1) [6, 11, 15–17]. Patients who shared
their PGx data with family members believed that
the results could be significant in improving the health of
their family members, while family members indicated
that they desired to receive genetic test results when they
were relevant and appreciated the information [18–20].
By sharing PGx results with family members, patients
can shed light on heritable instances of drug toxicity
or treatment failures that family members experienced in
the past.
A small number of studies—which included patients
who were willing to share results—also reported that some
patients did not want to share test results with providers
owing to concerns about computer confidentiality and
illiteracy or provider disinterest [21–23]. Patients also
indicated that they preferred a phone or in-person con-
versation for explanations of results [11]. In recent years,
providers have had increasing amounts of exposure to PGx
and have been trained to make clinical decisions based on
PGx results. In addition, studies have found that patients
preferred to receive web-based resources in tandem with a
lengthy conversation about PGx test results [15, 23, 24].
Moreover, issues related to privacy and HIPAA have been
improved with new technological platforms. For example,
platforms such as Amazon Web Services (AWS) and
G-suite by Google provide cloud-based services that are
both HIPAA compliant and secured. Thanks to growing
technological advancements and the prevalence of smart-
phones, patients can now easily access and view test results
via user-friendly mobile applications.
Sharing family pharmacogenomics data
Family history has long been used in clinical practice to
assess risk for many diseases (e.g., diabetes, cardiovascular
diseases). Additionally, family history has also been utilized
to determine if further screening is necessary for various
cancers, such as breast or colorectal cancers. Recent evi-
dence supports the investigation of the responses of first-
degree relatives to medications for patients with the same
disease [25]. For example, functional CYP2C19 activity is
required for the activation of clopidogrel in order to inhibit
platelet aggregation. If a patient has a history of recurrent
myocardial infarction or stroke post stent-placement despite
being on clopidogrel, it would be prudent to order PGx
testing to rule out the suboptimal CYP2C19 enzyme
activity. If the patient exhibits a poor metabolite phenotype,
their siblings and/or children would likely exhibit at least an
intermediate CYP2C19 phenotype. Other medications that
are metabolized by CYP2C19 may also require dose
adjustment or alternatives based on the CYP2C19 pheno-
type. Citalopram, escitalopram, tricyclic antidepressants,
voriconazole, and proton pump inhibitors are few of the
drugs that are metabolized by CYP2C19 and would likely
require such adjustments. Instead of genetically testing
every family member, the PGx data of one family member
could inherently be applied to members of the family who
present a similar medical scenario [25].
Pharmacogenomic cascade testing (PhaCT)
Cascade testing is a method that has been used to genetically
test for characterized diseases such as familial hypercholes-
terolemia, cancer, and certain arrhythmias [20, 26–28]. In
genetic testing for cancer, the traceback method has been used
to identify mutations in cancer patients who have not been
genetically tested. When a mutation is found through trace-
back, a cascade testing is then performed on at-risk family
members [28]. Tests are initially performed in a cascading
fashion using first-degree relatives owing to genetic simila-
rities or overlap [20]. Cascade testing provides patients that
have a family history of cancer with a confirmation of the
presence of allelic variations similar to that of the diagnosed
family members, and thus an opportunity for patients to act
proactively on their results. Therefore, traceback testing uses a
reactive approach of screening for putative mutations when
the diagnosis already exists in a patient, while cascade testing
prospectively uses family history data to identify mutations
preemptively among the at-risk family members.
The idea of cascade testing can be implemented in PGx
testing. However, cascade testing is not currently used in
PGx testing. The information from a patient’s PGx results
can help family members that may be concerned about
similar medication interactions to pursue a preemptive PGx
testing. For example, in Gennis et al., three siblings out of
12 developed phenytoin hypersensitivity reactions [29]. An
in vitro study of cells from the patients who exhibited
hypersensitivity reactions showed an increase in toxicity
from metabolites of phenytoin and carbamazepine. Four
other siblings from the same family who never took antic-
onvulsants also exhibited a high degree of toxicity from
phenytoin and carbamazepine metabolites in vitro. This
family highlights the inherited nature of phenytoin hyper-
sensitivity and its importance as a candidate for PGx cas-
cade testing. If one of the siblings had received PGx results
confirming the presence of HLA-B*15:02 or CYP2C9-
atypical metabolism—which predisposes them to Stevens-
Johnsons Syndrome (SJS), Toxic Epidermal Necrolysis
Syndrome (TENS), or other side effects—the results would
also be highly pertinent to the rest of the family members, as
well as their children. While PGx testing was not widely
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available at the time this study was conducted, this family is
a prime example of how an entire family could have ben-
efitted from the pharmacogenomics cascade testing (PhaCT)
method, which would have effectively identified a history of
sensitivity reactions to certain antiepileptic medications. As
PGx becomes more widely accessible, it is important that
patients share results with family members in order to
effectively identify individuals that are at risk for adverse
drug events or medication failures. Also, with the increasing
complexity of patients’ data from discrete sources, it is
imperative to integrate family PGx data to optimize therapy
outcomes for family members [30–33].
The future of integrated PhaCT
The Translational Pharmacogenetics Program (TPP) of the
National Institutes of Health (NIH) Pharmacogenomics
Research Network has discussed the diversity and varia-
bility in ordering, storing, and representing PGx results.
Although PGx data standards are offered by SNOMED CT
(Systemized Nomenclature of Human and Veterinary
Medicine, Clinical Terms), LOINC (Logical Observation
Identifiers Names and Codes), and Health Level Seven
International (HL7 v2, v3Clinical Document Architectures,
FHIR), the standards are not routinely implemented by PGx
labs or EHRs [34]. This lack of data standardization in PGx
results is a significant barrier to sharing results between
different healthcare systems, patients, and other providers.
Health Information Exchange (HIE) allows patient infor-
mation to be accessed throughout different levels of care
using an interoperable system. Although HIE initiatives
have been progressing since the HITECH Act in 2009, most
HIE occurs across healthcare systems and does not extend
to patients [35]. In contrast, sharing PGx data is an aspect of
HIE that would include patients in the accountability of
their health. Allowing patients to share PGx results with
their family members for preemptive testing in a HIPAA-
protected environment could be the key to engaging and
empowering patients. Ultimately, it is necessary to develop
PGx data in a structured, scalable, and EHR-agnostic
shareable format from various third-party laboratories. This
discrete model for PGx data will allow patients to easily
share PGx results with family members and use the results
for future generations as well.
In the current typical workflow of a PGx test (Fig. 1),
patients may view their results either as a pdf or other static
text format. An ancillary genomics system, capable of
storing and sharing discrete, computable data, has the
potential to improve the shareability of PGx results with
their family members, current and future providers. We
propose a potential model for sharing PGx results, which is
illustrated in Fig. 2. Once a PGx test is ordered by a pre-
scriber through either the EHR or a point-of-care web-basedTa
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platform, the lab sends the machine-readable data to an
ancillary patient-managed genomic system (PMGS), which
would be created for patients to review and manage their
results. The PMGS will also store a human-readable version
of the clinically actionable PGx results. PGx test results can
be accessed both by a mobile or web application, as well as
the EHR. Within the PMGS system, patients will have
access to the results and can share results with other clin-
icians or family members. Once shared by the patient, the
computable results in the EHR may employ CDS logic and
show actionable recommendations to the appropriate clin-
icians. In this model, both patients and providers have
access to the same results. Ultimately, patients are able to
share these results with family members, as well as with
other providers who might be part of a different medical
group. As a result, the patient is the gatekeeper of the PGx
results, and therefore is in control of sharing them.
This model will only be successful if visual and data
analytics are integrated into the design of the user platform
[36, 37]. A user-friendly design would encourage patients to
check PGx results easily whenever new medications are
being considered for their treatment plan. While previous
studies have investigated ideal visual and data analytics
platforms on the provider side, future research is needed to
investigate patient preferences and usability [36, 38]. With
an effective design, patients will be more motivated to share
and utilize results to improve decision making regarding
their health care in collaboration with their providers in
order to foster shared decision making.
One of the obstacles to implementing shared decision
making is engaging patients at every level of care [39].
However, by allowing patients to share results with family
members and providers, patients are actively involved at all
levels of health care decisions. Another benefit of patient
participation and a shareable platform is the potential to
decrease polypharmacy and complexity regarding medica-
tions [31, 36]. When patients have PGx results that are
easily accessible, patients will be able to utilize this tool to
check medications with providers at the point-of-care in
order to prevent duplications in therapy or unnecessary or
overly complicated therapy modalities. Using this model,
patients will fully understand the purpose of each medica-
tion as well as their treatment plan [11]. In addition, since
family members are aware of medications that are being
Fig. 2 A proposed integrative
model for operationalizing
pharmacogenomics data
sharing and
pharmacogenomic cascade
testing (PhaCT). In this model,
the ordering of the test, the
collection of the patient’s
sample, and the translation of
genomics data into clinically
actionable results will remain the
same. However, once the results
are finalized, they will be sent to
an ancillary patient-managed
genomic system (PMGS).
Within the PMGS system,
patients will have access to the
results and will be able to share
results with other clinicians or
family members. Lastly, the
PMGS could also have the
ability to send the results to the
electronic health record (EHR),
which could then be sent to the
prescribing physician.
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taken within the family, they can hold each other accoun-
table and share the responsibility of health management.
There is also a cause for concern regarding the ethical
and legal implications of sharing results with family mem-
bers [28]. Fortunately, with laws in place to protect patients
against genetic discrimination via the Genetic Information
Nondiscrimination Act (GINA) and often stricter state-
specific GINA protections, patients can be at peace with
sharing genomic information [19]. With a shareable plat-
form, patients will have the ability to decide how much
information to share with family members and for how
long. Currently, no laws are in place to prevent patients
from disclosing such information [19]. Most importantly,
sharing PGx results will be at the discretion of the patient.
However, physicians should encourage at-risk patients to
inform family members who could benefit from earlier
interventions [40].
Conclusions
By incorporating family medication history along with PGx
data, both HCPs and patients will be equipped with more
knowledge to determine the most appropriate therapy. More
specifically, an advanced CDS system that can leverage the
shared family PGx data may have the capability to adequately
support providers and patients in shared decision-making
[30, 41]. As discussed above, patients indicate that they are
not only willing to share results with providers but with
family members as well. Unfortunately, there are currently
barriers to the integration of family history with PGx data as
well as to allowing patients to share results with family. One
example of these barriers is the lack of security and privacy in
sharing results with others. However, recent advancements in
technology can address this issue by letting patients choose
precisely what to share and with whom to share it.
In the future, the use of family history information and
PGx data have the potential to improve patient clinical
outcomes by incorporating PhaCT at a national level. By
integrating PhaCT, patients can rely on the PMGS to
ascertain whether a family member requires preemptive
PGx testing. PhaCT can have a significant positive impact
on getting insurance reimbursement for PGx testing. Once
providers review family members’ results, the case for
ordering a PGx test can be substantial to save the patient
from potentially similar adverse drug reactions previously
experienced by others in the family. Thus, insurance com-
panies may have a stronger motivation to reimburse for PGx
testing to reduce overall healthcare costs. By sharing results,
patients are integrated into their own health care experience,
as well as that of their family. Future studies are needed to
explore the features of PMGS with user-friendly visual
analytics for PGx data sharing.
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